Myelodysplastic syndrome eb2 is a high-risk clonal malignant disease of the hematologic system that is more serious. Because myelodysplastic syndrome eb2 has a poor prognosis and a low cure rate, the only way to cure it is to have a hematopoietic stem cell transplant, but if you can’t have the surgery for various reasons, it will have a direct impact on the therapeutic effect of the disease, and it can be life-threatening due to the progression of the disease in a short period of time, which is why myelodysplastic syndrome eb2 is more serious. Some patients with myelodysplastic syndrome eb2 may have thrombocytopenia, severe anemia and infections, etc., which require timely supportive treatment. If platelets are not replenished in time, it may cause bleeding tendency, which is mainly manifested as bleeding from skin and mucous membranes or bleeding from organs, so the disease is more serious. After the discovery of myelodysplastic syndrome eb2, it is recommended to carry out treatment as soon as possible to avoid delaying the condition, but the specific medication program should be strictly in accordance with the doctor’s instructions.